Covaxin supply suspension by WHO not to impact travel by people: MEA clarifies

New Delhi, April 08: Clearing confusion, the Ministry of External Affairs has informed that the World Health Organisation suspension of Covaxin Supply through UN procurement agencies 'will not have an impact on travel.'

 

 

While responding to the question, MEA spokesperson Arindam Bagchi, informed that in terms of their travel, the vaccine continues to be recognised under the emergency use listing of WHO and various countries have already accepted it.

 

 

"I think there has been a statement issued by Bharat Biotech as well as from WHO, both of which are very clear in emphasising that the vaccine is safe, its effective. Its efficacy is not in question," Bagchi said at the regular media briefing.

 

"There is something about process issues that are being worked out between the company and WHO. You will have to ask them about the details," he added.

 

Bagchi further added, "I don`t think that`s a cause for worry at all" as India has mutual recognition of vaccination certificate arrangements with various countries.

 

Covaxin, an Indigenous COVID-19vaccine, is produced by Hyderabad-based Bharat Biotech. Last week, WHO informed that it has suspended supply through UN agencies of Covaxin in response to the need to conduct process and facility upgrades to address recently identified GMP(Good Manufacturing practice) deficiencies. It should be noted that the UN body, however, has clarified that there are no issues related to the safety and efficacy of calls for an independent investigation.

.

.